Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $9.00.

A number of equities research analysts have recently weighed in on the stock. HC Wainwright initiated coverage on shares of Senti Biosciences in a report on Tuesday, October 14th. They set a “buy” rating and a $12.00 price objective on the stock. Leerink Partnrs raised Senti Biosciences to a “strong-buy” rating in a research report on Friday, November 21st. Wall Street Zen upgraded Senti Biosciences to a “sell” rating in a research note on Saturday, December 13th. Leerink Partners initiated coverage on Senti Biosciences in a research note on Friday, November 21st. They issued an “outperform” rating and a $6.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a report on Wednesday, October 8th.

Senti Biosciences Stock Up 2.8%

SNTI stock opened at $1.11 on Friday. The firm has a 50 day moving average of $1.59 and a 200 day moving average of $1.70. The stock has a market capitalization of $29.18 million, a PE ratio of -0.33 and a beta of 2.13. Senti Biosciences has a 52 week low of $1.04 and a 52 week high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). On average, equities research analysts expect that Senti Biosciences will post -14.54 earnings per share for the current year.

Institutional Trading of Senti Biosciences

Large investors have recently made changes to their positions in the business. Armistice Capital LLC acquired a new stake in shares of Senti Biosciences in the second quarter worth $1,883,000. Geode Capital Management LLC lifted its position in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the period. Finally, Citadel Advisors LLC purchased a new stake in Senti Biosciences in the third quarter valued at $117,000. 25.70% of the stock is owned by hedge funds and other institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.